Iwasawa et al present on use of a novel irrigated ablation catheter with a diamond-embedded tip for rapid cooling to improve thermal feedback. The catheter also included high resolution electrograms from split tip electrodes. They tested the catheter in both pigs and humans for evaluation of utility in pulmonary vein isolation. In patients, they compared use of the novel catheter against a control group using a standard catheter with plan to remap for pulmonary vein reconnection after 3 months. In porcine hearts, they demonstrated a high frequency of transmurality with lesion application with the novel catheter. In the patient example, there was significantly less ablation time needed to achieve PVI compared to standard catheters (26 vs 90 minutes) and there was less frequent of apparent acute dormant pulmonary vein conduction. The majority of patients (74%) had durable PV isolation at the time of remapping. Commentary: This is the first study of a novel catheter consisting of a diamond embedded tip and novel thermocouple distribution to facilitate temperature controlled irrigated radiofrequency ablation. In a small subset of patients, using less ablation duration with shorter fluoroscopy times, there was a high frequency of durable PV isolation (though the control group was not remapped). Given the ongoing evolution of catheters for the purpose of achieving more effective or more efficient cardiac ablation, consideration of new designs and their implications on safety and efficacy is critical. This reflects the first study of this novel catheter, though further randomized analysis to prove incremental benefit is required. 10.1016/j.jacep.2017.02.018 
Idarucizumab for Dabigatran Reversal -Full Cohort Analysis
Summary: Pollack et al review the full analysis of idarucizumab for achieving dabigatran reversal. In this multicenter, prospective open-label study, they studied whether or not idarucizumab could completely reverse the effects of dabigatran safely in those with uncontrolled bleeding or about to undergo an urgent invasive procedure. A total of 503 patients were included and median maximum percentage reversal was 100%. In those with uncontrolled bleeding, mean time to bleeding cessation was 2.5 hours. In those undergoing surgery, periprocedural hemostasis was considered normal in 93% of patients performed an average 1.6 hours after administration. Thrombotic events were seen in 6.3% of the uncontrolled bleeding cohort and 7.4% of the surgery cohort, with mortality rates above 18% in each group. Commentary: Overall, these data demonstrate a high level of safety and efficacy in use of idarucizumab for rapid reversal of dabiagatran in acute situations. While the outcomes suggest a high incidence of thrombotic events and mortality, these patients reflected a high-risk cohort overall given the presence of uncontrolled bleeding or need for urgent surgery for various indications. Whether the thrombotic risk after immediate reversal is reflective of a prothrombotic state in the immediate post reversal period that exceeds normal situations where a patient is either not on a blood thinner, is on a blood thinner but allowed to gradually have it wear out, or is on a different blood thinner such as warfarin which is subsequently reversed is unclear.
10.1136/heartjnl-2016-310672
Early non-persistence with dabigatran and rivaroxaban in patients with atrial fibrillation Summary: Jackevicius, et al report the persistence of patients on therapy with novel oral anticoagulants when compared with warfarin. The justification for their study was that while NOACs are increasingly being utilized in clinical practice, the lack of monitoring strategies to ensure patients are compliant with the prescription is not as straightforward as with warfarin where checking an INR may give that information. In this retrospective cohort study, non-persistence was defined as a gap of at least 14 days in NOAC prescription. Amongst almost 16,000 dabigatran users and over 10,000 rivaroxaban users, around a third were not persistent with their medication. Stroke, TIA, and death were more common in those patients who were non-persistent with their NOAC prescription. Commentary: These findings support the importance of clinical counseling of patients on the importance of being persistent with their anticoagulant prescription in the setting of novel oral anticoagulants. Novel oral anticoagulants, while easier to use given the lack of need for blood monitoring, are also exposed to the confirmation issues regarding their continued compliance. These data highlight the importance of counseling patients on the increased risk of incident stroke, TIA, or death that may occur with failure to persist with anticoagulant prescriptions.
10.1093/eurheartj/ehx403
Predictors of pre-procedural concentrations of direct oral anticoagulants: a prospective multicentre study Summary: Godier, et al reviewed in a prospective multicenter study the various predictors of direct oral anticoagulant concentrations prior to procedures. Amongst 422 patients, there was a wide range of time of cessation relative to the procedure timing, but it was demonstrated that after a 49-72 hour period of discontinuation, nearly 95% of the anticoagulant was at a low enough level to be considered safe to proceed. A 72 hour period of discontinuation predicted a low residual DOAC level with 91% specificity. However, low creatinine clearance and antiarrhythmic use were predictors of needing a longer tiem off DOACs to achieve a low concentration (with the former being more relevant for dabigatran and the latter for anti-Xa treated patients). They also demonstrated the routine hemostasis assays did not correlate with DOAC concentrations.
Commentary:
The study by Godier, et al highlights that a 72 hour period of DOAC discontinuation can predictably result in a low enough concentration as to be safe to proceed with an invasive procedure. However, certain factors such as antiarrhythmic use or moderate renal impairment predicted the need for longer duration off a DOAC prior to achieving a low enough DOAC concentration to be safe to proceed with an invasive procedure. These data can be used to guide hospital policies on peri-procedural anticoagulant management.
10.1007/s10840-017-0274-2 The anticoagulant effect of heparin during radiofrequency ablation (RFA) in patients taking apixaban or rivaroxaban Summary: Brendel, et al reviewed the role of heparinization during ablation on apixaban and rivaroxaban given the activated clotting time (ACT) does not often reflect accurately the total anticoagulant effect. 90 patients were assessed in terms of anticoagulant effect on either rivaroxaban or apixaban while on heparin targeted to an ACT of 250-300 seconds based on blood samples taken 10, 60, and 360 minutes after heparin administration. Rivaroxaban-treated patients exhibited
